Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mimicking the human environment in mice reveals that inhibiting biotin biosynthesis is effective against antibiotic-resistant pathogens

Nature Microbiology volume 5, pages 93–101 (2020)Cite this article

Subjects

Abstract

To revitalize the antibiotic pipeline, it is critical to identify and validate new antimicrobial targets1. In Mycobacteria tuberculosis and Francisella tularensis, biotin biosynthesis is a key fitness determinant during infection2,3,4,5, making it a high-priority target. However, biotin biosynthesis has been overlooked for priority pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. This can be attributed to the lack of attenuation observed for biotin biosynthesis genes during transposon mutagenesis studies in mouse infection models6,7,8,9. Previous studies did not consider the 40-fold higher concentration of biotin in mouse plasma compared to human plasma. Here, we leveraged the unique affinity of streptavidin to develop a mouse infection model with human levels of biotin. Our model suggests that biotin biosynthesis is essential during infection with A. baumannii, K. pneumoniae and P. aeruginosa. Encouragingly, we establish the capacity of our model to uncover in vivo activity for the biotin biosynthesis inhibitor MAC13772. Our model addresses the disconnect in biotin levels between humans and mice, and explains the failure of potent biotin biosynthesis inhibitors in standard mouse infection models.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Presence of a high-affinity biotin transporter in pathogens accounts for variation in biotin requirements.
Fig. 2: Biotin biosynthesis is essential for A. baumannii, K. pneumoniae and P. aeruginosa during an infection mimicking human biotin levels.
Fig. 3: Crystal structure of E. coli BioA in complex with MAC13772.
Fig. 4: In vivo efficacy of biotin biosynthesis inhibition.

Data availability

The crystal structure of E. coli BioA in complex with MAC13772 solved to 2.4 Å has been deposited to the Protein Data Bank with accession code 6ED7. The source data underlying Figs. 1d and 4a–c, are provided as Supplementary Data Tables 2–9. The data supporting the findings of this study are available from the corresponding author on reasonable request.

References

  1. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336–343 (2016).

    CAS  PubMed  Google Scholar 

  2. Sassetti, C. M. & Rubin, E. J. Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad. Sci. USA 100, 12989–12994 (2003).

    CAS  PubMed  Google Scholar 

  3. Weiss, D. S. et al. In vivo negative selection screen identifies genes required for Francisella virulence. Proc. Natl Acad. Sci. USA 104, 6037–6042 (2007).

    CAS  PubMed  Google Scholar 

  4. Napier, B. A. et al. Link between intraphagosomal biotin and rapid phagosomal escape in Francisella. Proc. Natl Acad. Sci. USA 109, 18084–18089 (2012).

    CAS  PubMed  Google Scholar 

  5. Park, S. W. et al. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 7, e1002264 (2011).

    CAS  Google Scholar 

  6. Wang, N., Ozer, E. A., Mandel, M. J. & Hauser, A. R. Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung. mBio 5, e01163–14 (2014).

    PubMed  PubMed Central  Google Scholar 

  7. Subashchandrabose, S. et al. Acinetobacter baumannii genes required for bacterial survival during bloodstream infection. mSphere 1, e00013–e00015 (2016).

    PubMed  Google Scholar 

  8. Bachman, M. A. et al. Genome-wide identification of Klebsiella pneumoniae fitness genes during lung infection. mBio 6, e00775–15 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Skurnik, D. et al. A comprehensive analysis of in vitro and in vivo genetic fitness of Pseudomonas aeruginosa using high-throughput sequencing of transposon libraries. PLoS Pathog. 9, e1003582 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Crofts, A. A. et al. Enterotoxigenic E. coli virulence gene regulation in human infections. Proc. Natl Acad. Sci. USA 115, 8968–8976 (2018).

    Google Scholar 

  11. Sheikh, A. et al. In vivo expression of Salmonella enterica serotype Typhi genes in the blood of patients with typhoid fever in Bangladesh. PLoS Negl. Trop. Dis. 5, e1419 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Subashchandrabose, S., Smith, S. N., Spurbeck, R. R., Kole, M. M. & Mobley, H. L. T. Genome-wide detection of fitness genes in uropathogenic Escherichia coli during systemic infection. PLoS Pathog. 9, e1003788 (2013).

    PubMed  PubMed Central  Google Scholar 

  13. Silva-Valenzuela, C. A. et al. Analysis of two complementary single-gene deletion mutant libraries of Salmonella Typhimurium in intraperitoneal infection of BALB/c mice. Front. Microbiol. 6, 1–9 (2016).

    Google Scholar 

  14. Valentino, M. D. et al. Genes contributing to Staphylococcus aureus fitness in abscess- and infection-related ecologies. mBio 5, e01729–14 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Streit, W. R. & Entcheva, P. Biotin in microbes, the genes involved in its biosynthesis, its biochemical role and perspectives for biotechnological production. Appl. Microbiol. Biotechnol. 61, 21–31 (2003).

    CAS  PubMed  Google Scholar 

  16. Lin, S., Hanson, R. E. & Cronan, J. E. Biotin synthesis begins by hijacking the fatty acid synthetic pathway. Nat. Chem. Biol. 6, 682–688 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Okami, Y. et al. Studies on a new amino acid antibiotic, amiclenomycin. J. Antibiot. 27, 656–664 (1974).

    CAS  PubMed  Google Scholar 

  18. Kitahara, T., Hotta, K., Yoshida, M. & Okami, Y. Biological studies on amiclenomycin. J. Antibiot. 28, 215–222 (1975).

    CAS  PubMed  Google Scholar 

  19. Dai, R., Wilson, D. J., Geders, T. W., Aldrich, C. C. & Finzel, B. C. Inhibition of Mycobacterium tuberculosis transaminase BioA by aryl hydrazines and hydrazides. Chembiochem 15, 575–586 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Park, S. W. et al. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem. Biol. 22, 76–86 (2015).

    CAS  PubMed  Google Scholar 

  21. Liu, F. et al. Structure-based optimization of pyridoxal 5′-phosphate-dependent transaminase enzyme (BioA) inhibitors that target biotin biosynthesis in Mycobacterium tuberculosis. J. Med. Chem. 60, 5507–5520 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Salaemae, W., Booker, G. W. & Polyak, S. W. Genetic requirements for mycobacterial survival during infection. Microbiol. Spectr. 4, VMBF-0008-2015 (2016).

    Google Scholar 

  23. Mock, D. M. & Malik, M. I. Distribution of biotin in human plasma: most of the biotin is not bound to protein. Am. J. Clin. Nutr. 56, 427–432 (1992).

    CAS  PubMed  Google Scholar 

  24. Trüeb, R. M. Serum biotin levels in women complaining of hair loss. Int. J. Trichology 8, 73–77 (2016).

    PubMed  PubMed Central  Google Scholar 

  25. Harthe, C. & Claustrat, B. A sensitive and practical competitive radioassay for plasma biotin. Ann. Clin. Biochem. 40, 259–263 (2003).

    CAS  PubMed  Google Scholar 

  26. Perry, C. A. et al. Pregnancy and lactation alter biomarkers of biotin metabolism in women consuming a controlled diet. J. Nutr. 144, 1977–1984 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Wakabayashi, K. et al. Serum biotin in Japanese children: enzyme-linked immunosorbent assay measurement. Pediatr. Int. 58, 872–876 (2016).

    CAS  PubMed  Google Scholar 

  28. Whiteside, M. D., Winsor, G. L., Laird, M. R. & Brinkman, F. S. L. OrtholugeDB: a bacterial and archaeal orthology resource for improved comparative genomic analysis. Nucleic Acids Res. 41, 366–376 (2013).

    Google Scholar 

  29. Zlitni, S., Ferruccio, L. F. & Brown, E. D. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat. Chem. Biol. 9, 796–804 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Tiwari, D. et al. Targeting protein biotinylation enhances tuberculosis chemotherapy. Sci. Transl. Med. 10, eaal1803 (2018).

    PubMed  PubMed Central  Google Scholar 

  31. El Zahed, S. S. & Brown, E. D. Chemical–chemical combinations map uncharted interactions in Escherichia coli under nutrient stress. iScience 2, 168–181 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Legrand, N. et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6, 5–9 (2009).

    CAS  PubMed  Google Scholar 

  33. Lin, S. & Cronan, J. E. The BioC O-methyltransferase catalyzes methyl esterification of malonyl-acyl carrier protein, an essential step in biotin synthesis. J. Biol. Chem. 287, 37010–37020 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Ploux, O., Breyne, O., Carillon, S. & Marquet, A. Slow-binding and competitive inhibition of 8-amino-7-oxopelargonate synthase, a pyridoxal-5′-phosphate-dependent enzyme involved in biotin biosynthesis, by substrate and intermediate analogs. Eur. J. Biochem. 259, 63–70 (1999).

    CAS  PubMed  Google Scholar 

  35. Hanka, L. J., Martin, D. G. & Reineke, L. M. Two new antimetabolites of biotin: α-methyldethiobiotin and α-methylbiotin. Antimicrob. Agents Chemother. 1, 135–138 (1972).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Eisenberg, M. A. & Hsiung, S. C. Mode of action of the biotin antimetabolites actithiazic acid and α-methyldethiobiotin. Antimicrob. Agents Chemother. 21, 5–10 (1982).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Alexeev, D. et al. Rational design of an inhibitor of dethiobiotin synthetase; interaction of 6-hydroxypyrimindin-4(3H)-one with the adenine base binding site. Tetrahedron 54, 15891–15898 (1998).

    CAS  Google Scholar 

  38. Bockman, M. R. et al. Investigation of (S)-(−)-acidomycin: a selective antimycobacterial natural product that inhibits biotin synthase. ACS Infect. Dis. 5, 598–617 (2019).

    CAS  PubMed  Google Scholar 

  39. Taira, J. et al. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. J. Antibiot. 70, 1057–1064 (2017).

    CAS  PubMed  Google Scholar 

  40. Datta, S., Costantino, N. & Court, D. L. A set of recombineering plasmids for Gram-negative bacteria. Gene 379, 109–115 (2006).

    CAS  PubMed  Google Scholar 

  41. Datsenko, Ka & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640–6645 (2000).

    CAS  PubMed  Google Scholar 

  42. Huang, T. W. et al. Capsule deletion via a λ-Red knockout system perturbs biofilm formation and fimbriae expression in Klebsiella pneumoniae MGH 78578. BMC Res. Notes 7, 13 (2014).

    PubMed  PubMed Central  Google Scholar 

  43. Gallagher, L. A. et al. Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii. J. Bacteriol. 197, 2027–2035 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Held, K., Ramage, E., Jacobs, M., Gallagher, L. & Manoil, C. Sequence-verified two-allele transposon mutant library for Pseudomonas aeruginosa PAO1. J. Bacteriol. 194, 6387–6389 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Fey, P. D. et al. A genetic resource for rapid and comprehensive phenotype screening of nonessential Staphylococcus aureus genes. mBio 4, e00537–12 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D 66, 213–221 (2010).

    CAS  Google Scholar 

  47. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 60, 2126–2132 (2004).

    Google Scholar 

  48. Mann, S., Eveleigh, L., Lequin, O. & Ploux, O. A microplate fluorescence assay for DAPA aminotransferase by detection of the vicinal diamine 7,8-diaminopelargonic acid. Anal. Biochem. 432, 90–96 (2013).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank S. McCusker from the Centre for Microbial Chemical Biology and G. Wright for bacterial strains from the Institute for Infectious Disease Research clinical collection, A. Fiebig-Comyn for amendments to the animal use protocol, National Institute of Allergy and Infectious Diseases preclinical services for pharmacokinetic testing, A. Eakin for advice and guidance (contract HHSN272201100022I awarded to SRI, International) and R. Melano at Public Health Ontario for bacterial strains GB687 and C0064. This research was supported by a Foundation grant from the Canadian Institutes for Health Research (FDN-143215), a donation from the Boris Family Foundation and by funding from the Ontario Research Fund Research Excellence program (RE07-048). E.D.B. was supported by a salary award from the Canada Research Chairs program. L.A.C. was supported by an Ontario Graduate Scholarship Award and a Canadian Institutes for Health Research scholarship.

Author information

Authors and Affiliations

  1. Michael G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada

    Lindsey A. Carfrae, Craig R. MacNair, Christopher M. Brown, Caressa N. Tsai, Brent S. Weber, Soumaya Zlitni, Vishwas N. Rao, Joshua Chun, Brian K. Coombes & Eric D. Brown

  2. Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA

    Soumaya Zlitni

  3. Department of Biochemistry, Western University, London, Ontario, Canada

    Murray S. Junop

Authors
  1. Lindsey A. Carfrae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig R. MacNair
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher M. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caressa N. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brent S. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Soumaya Zlitni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vishwas N. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joshua Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Murray S. Junop
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Brian K. Coombes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eric D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.A.C. conceived the research, designed and carried out experiments and data analysis, and wrote the manuscript. C.R.M. assisted with data acquisition and interpretation and manuscript editing. L.A.C designed and conducted the in vitro assays to determine biotin requirement and in vitro enzyme assays. C.N.T. performed the orthologue search and phylogenetic analysis. L.A.C. and B.S.W. designed and performed the plasma growth assays. C.M.B., S.Z. and J.C. designed and performed crystallization experiments and C.M.B performed the analysis with input from M.S.J. L.A.C. and V.N.R. performed susceptibility testing. L.A.C and C.R.M. designed and performed in vivo infection model experiments. B.S.W., M.S.J. and B.K.C. assisted with data interpretation. E.D.B. conceived the research and assisted with data interpretation and manuscript editing.

Corresponding author

Correspondence to Eric D. Brown.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Biotin requirements of BioA deficient strains represent the entirety of the biosynthetic pathway.

Analysis of the biotin concentrations required to restore growth of (a) A. baumannii transposon mutants in bioACDF and (b) E. coli ΔbioABCDF in M9 minimal media supplemented with amino acids after 18 hours. Points show the mean of 8 replicates ± s.d. and the solid lines show a four-parameter dose response curve. (c) Presence or absence of a high-affinity biotin transporter in a phylogenetic tree of pathogenic bacteria with an ortholog to E. coli BioA. The presence of an ortholog to biotin transporters, E. coli BioP and S. aureus BioY was determined using OrtholugeDB. Species with a predicted ortholog to E. coli BioP (green) or S. aureus BioY (blue) transporters are demarked by a circle.

Extended Data Fig. 2 Biotin levels are comparable among three common mouse strains.

(a) Quantification of biotin levels in purchased human and mouse plasma from Innovative Research. Each point represents a technical replicate (n = 4) and the line is the mean. (b) Quantification of biotin in the plasma of BALB/c (n = 6), CD-1 (n = 7), and C57Bl/6 (n = 8) mice. Each point represents the biotin levels of a single mouse and the line is the mean. (c) Fold change in viable cell counts of BioA deficient (grey) and wild-type (black) A. baumannii (AB), K. pneumoniae (KP), P. aeruginosa (PA), and S. Typhimurium (ST) growth after 24 hours in 50% human plasma supplemented with biotin (10 µg/mL). BioA deficient or wild-type strains were separately inoculated into plasma diluted with M9 salts supplemented with 25 mM of sodium bicarbonate. Viable cell counts were calculated at time 0 and 24 hours. Fold change was calculated by dividing the viable cell count at 24 hours by the viable cell count at time 0. The bars indicate the mean of 6 replicates ± s.d.

Extended Data Fig. 3 Biotin biosynthesis is dispensable for A. baumannii, K. pneumoniae, P. aeruginosa, S. aureus, and S. Typhimurium during standard infection models.

Bacterial load in the blood, spleen, kidneys, liver, and lungs following a systemic infection with (a) A. baumannii (AB; n = 5), (b) K. pneumoniae (KP; n=10), (c) P. aeruginosa (PA; n=9), (d) S. aureus (SA; n=6), and (e) S. Typhimurium (ST; n=5). Mice were co-infected with a mixed inoculum of wild- type (grey) and BioA deficient (black) bacteria inoculated by intraperitoneal injection. (f) Bacterial load in the lungs of mice co-infected with a mixed inoculum of wild-type (grey) and ΔbioA (black) bacteria. Infection was established by intranasal administration of 2×107 CFU by micropipette and mice (n=10) euthanized 36 hours later. (g) Bacterial load in the thighs of mice co-infected with a mixed inoculum of wild-type (grey) and BioA deficient (black) A. baumannii (AB; n=6), K. pneumoniae (KP; n=8), P. aeruginosa (PA; n=4), and S. aureus (SA; n=10). 5×105 (KP and SA) or 5×106 (AB and PA) CFU were injected into the thighs of mice. In all instances box plot whiskers show the minimum to maximum values, the box denotes the interquartile range, and the line in the box shows the median.

Extended Data Fig. 4 Determination of an optimal dose of streptavidin to mimic human biotin levels.

Quantification of biotin in the plasma of CD-1 mice following intraperitoneal administration of (a) streptavidin (1 mg/kg) or (b) streptavidin (4 mg/kg) treatment. Each point represents the biotin levels of a single mouse (n = 2–7) and the line indicates the mean. The grey area indicates the typical range of human biotin concentration in plasma accounting for daily fluctuations. (c) Streptavidin pretreatment has no effect on the ability of wild-type bacteria to cause infection. A. baumannii bacterial load in the blood, spleen, kidney, liver, and lungs in a standard infection model (n=6) or mice pretreated with streptavidin (2 mg/kg; n=4). Mice were infected by intraperitoneal injection and euthanized 10 hours post- infection. Each point represents the bacterial load from an individual mouse and the line indicates the mean.

Extended Data Fig. 5 Biotin biosynthesis is a critical fitness determinant for A. baumannii, K. pneumoniae, and P. aeruginosa during a systemic infection with human biotin levels.

Competitive index (CI) for the co-infection of BioA deficient and wild-type strains of (a) A. baumannii (n=5, 8), (b) K. pneumoniae (n=10, 8), (c) P. aeruginosa (n=9, 8), and (d) S. aureus (n=6, 9) in the blood, spleen, kidneys, liver, and lungs in a standard systemic infection model (light blue) or systemic infection in mice pretreated with streptavidin (2 mg/kg; blue) 1-hour prior to inoculation. CI is calculated by dividing the bacterial load of the query strain (BioA deficient) by the bacterial load of the wild-type strain. Each point represents the CI from an individual mouse and the line indicates the mean. The dotted line represents a CI of 1 indicating the two strains are proliferating equally in vivo. Groups were analyzed with an unpaired two-tailed t-test and corrected for multiple comparisons with a Holm-Sidak test, * indicates a p<0.01.

Extended Data Fig. 6 Biotin biosynthesis is a critical fitness determinant for A. baumannii, K. pneumoniae, and P. aeruginosa during a systemic infection with human biotin levels.

Bacterial load in the blood, spleen, kidneys, liver, and lungs following a systemic infection with human biotin levels with (a) A. baumannii (n=8), (b) K. pneumoniae (n=8), (c) P. aeruginosa (n=8), and (d) S. aureus (n=9). Mice were pretreated with streptavidin (2 mg/kg) 1-hour prior to co- infection with a mixed inoculum of wild-type (grey) and BioA deficient (black) bacteria. Box plot whiskers show the minimum to maximum values, the box denotes the interquartile range, and the line in the box shows the median of each group. Groups were analyzed with an unpaired two-tailed t-test and corrected for multiple comparisons with a Holm-Sidak test, * indicates a p<0.01.

Extended Data Fig. 7 Biotin biosynthesis is dispensable during colonization of a systemic murine infection mimicking human biotin levels.

Bacterial load in the blood, spleen, kidneys, liver, and lungs 1- hour post-infection following a systemic infection with human biotin levels with (a) A. baumannii (AB; n=3), (b) K. pneumoniae (KP; n=2), and (c) P. aeruginosa (PA; n=3). Mice were pretreated with streptavidin (2 mg/kg) 1-hour prior to co- infection with a mixed inoculum of wild-type (grey) and BioA deficient (black) bacteria. Each point represents the bacterial load from an individual mouse and the line indicates the mean.

Extended Data Fig. 8 Resistance to inhibition of biotin biosynthesis imparts a fitness cost.

Kinetics of (7,8)-di-amino-pelargonic acid production. Initial velocities of (7,8)-di-amino-pelargonic acid production with BioA, BioAW52A, BioAK274A, BioAF393A, and BioAY398A were determined at various (a) (S)-keto-amino-pelargonic acid (KAPA; n=4) and (b) S-adenosyl-L-methionine (SAM; n=6) concentrations. Points show the mean of replicates ± s.d. and the solid lines show a Michaelis-Menten curve. (c) Analysis of the biotin concentrations required to restore growth of BioA deficient A. baumannii passaged into the lowest biotin concentration supporting growth for 14 days. Points show the mean of 8 replicates ± s.d. and the solid lines show a four- parameter dose response curve.

Extended Data Fig. 9 MAC13772 is efficacious against A. baumannii in a systemic infection with human biotin levels.

Bacterial load of A. baumannii in the blood, spleen, kidneys, liver, and lungs following a systemic infection with (a) standard biotin levels and (b) human biotin levels, treated with MAC13772 (15 mg/kg). Mice were pretreated with streptavidin (2 mg/kg) 1-hour prior infection and treated with MAC13772 (15 mg/kg) 1-hour following infection. Groups were analyzed with an unpaired two-tailed t-test and corrected for multiple comparisons with a Holm-Sidak test, * indicates a p<0.01. (c) Time course of plasma concentrations of MAC13772 in male (black) and female (grey) Sprague Dawley rats, after intravenous administration. Each data point represents the mean ± s.d. concentration from n=3 rats, the dotted line indicates the limit of quantification (LOQ).

Supplementary information

Supplementary Information

Supplementary Tables 1, 3–6 and 8–11, legends for Supplementary Tables 2 and 7, Supplementary Figures 1–3 and Supplementary References.

Reporting Summary

Supplementary Tables 2 and 7

Supplemental Table 2: OrtholugeDB predictions for the presence of an orthologue to E. coli BioP and S. aureus BioY. Supplemental Table 7: prediction of the presence of Phe393, Tyr144, Trp52, Tyr398 and Lys274 in 100 bacteria.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carfrae, L.A., MacNair, C.R., Brown, C.M. et al. Mimicking the human environment in mice reveals that inhibiting biotin biosynthesis is effective against antibiotic-resistant pathogens. Nat Microbiol 5, 93–101 (2020). https://doi.org/10.1038/s41564-019-0595-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41564-019-0595-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research